CA3023305C - COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES - Google Patents

COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Info

Publication number
CA3023305C
CA3023305C CA3023305A CA3023305A CA3023305C CA 3023305 C CA3023305 C CA 3023305C CA 3023305 A CA3023305 A CA 3023305A CA 3023305 A CA3023305 A CA 3023305A CA 3023305 C CA3023305 C CA 3023305C
Authority
CA
Canada
Prior art keywords
dosage form
valerian
pharmaceutical dosage
composition
release portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3023305A
Other languages
English (en)
French (fr)
Other versions
CA3023305A1 (en
Inventor
Syed M. Shah
Christopher Diorio
Daniel Hassan
Fred Hassan
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Publication of CA3023305A1 publication Critical patent/CA3023305A1/en
Application granted granted Critical
Publication of CA3023305C publication Critical patent/CA3023305C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3023305A 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES Active CA3023305C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332728P 2016-05-06 2016-05-06
US62/332,728 2016-05-06
PCT/US2017/031046 WO2017192843A1 (en) 2016-05-06 2017-05-04 Valerian composition and related methods

Publications (2)

Publication Number Publication Date
CA3023305A1 CA3023305A1 (en) 2017-11-09
CA3023305C true CA3023305C (en) 2024-07-02

Family

ID=60203773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023305A Active CA3023305C (en) 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Country Status (10)

Country Link
US (4) US10342873B2 (enExample)
EP (1) EP3452020A4 (enExample)
JP (2) JP7576905B2 (enExample)
KR (1) KR20190008265A (enExample)
CN (2) CN117482062A (enExample)
AU (1) AU2017260019A1 (enExample)
CA (1) CA3023305C (enExample)
MX (1) MX2018013569A (enExample)
RU (1) RU2018142019A (enExample)
WO (1) WO2017192843A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090315A1 (en) * 2020-01-17 2022-11-23 Société des Produits Nestlé S.A. Dosage form with sustained release melatonin pellets
IT202200013576A1 (it) * 2022-06-27 2023-12-27 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato a rilascio differenziato di melatonina e principi attivi

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699075A1 (fr) 1992-12-11 1994-06-17 Rech Sarl Ab Préparation médicinale à libération programmable dans le temps notamment à base de plantes.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2727315A1 (fr) 1994-11-30 1996-05-31 Cooperative Agricole Laitiere Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
CA2379395A1 (en) 1999-07-21 2001-02-01 Ancile Pharmaceuticals, Inc. Process for the extraction of valerian root
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
JP4532903B2 (ja) 2001-12-20 2010-08-25 アルペックス ファーマ ソシエテ アノニム 微粒子組成物
JP4951162B2 (ja) * 2004-04-06 2012-06-13 太陽化学株式会社 睡眠改善用組成物
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
CA2583794C (en) 2004-10-11 2015-05-26 Nasaleze Ppm Limited Compositions for intranasal administration
ZA200711048B (en) 2005-06-22 2009-05-27 Takeda Pharmaceutical Tablet containing hardly soluble active incredient
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
CN1850212A (zh) * 2006-02-28 2006-10-25 潮州市强基制药厂 一种缬草油液体硬胶囊及其制备方法
ES2452342T3 (es) 2006-09-27 2014-04-01 Finzelberg Gmbh & Co. Kg Preparación de extracto de valeriana
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20090197974A1 (en) * 2008-02-05 2009-08-06 Khaleeq Ahmed Natural dietary supplement tablet
EP2389350A1 (en) 2009-01-23 2011-11-30 Valericon GmbH Methods for making valerenic acid derivatives and their use
US20110064712A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN102370833B (zh) * 2010-08-17 2014-03-26 北京亚东生物制药有限公司 一种解表祛暑的泡腾剂及其制备方法和用途
CN102058630B (zh) * 2010-12-16 2014-03-19 苏州大学 一种镇静安神的缬草制剂及其制备方法
CN102247443A (zh) 2010-12-23 2011-11-23 祝凤仪 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法
JP5600747B2 (ja) 2011-01-17 2014-10-01 武田薬品工業株式会社 口腔内分散性製剤
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
CN102114060B (zh) * 2011-02-22 2012-12-12 都晓伟 黑水缬草提取物及其制备方法和应用
JP2013053144A (ja) * 2011-08-09 2013-03-21 Daiichi Sankyo Healthcare Co Ltd 鎮静剤組成物
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
JP2015509708A (ja) 2012-01-26 2015-04-02 ウィキフーズ，インコーポレイテッド 材料の天然輸送系内への封入
CA2928777A1 (en) 2012-11-09 2014-06-05 Abattis Bioceuticals Corp. Nitric oxide increasing nutritional supplements and methods
US20140271890A1 (en) 2013-03-14 2014-09-18 Thaer Ahmad Controlled-release pharmaceutical composition
BR112015006499A2 (pt) 2013-04-23 2017-07-04 Zx Pharma Llc composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados
PL231923B1 (pl) 2013-10-28 2019-04-30 Proteon Pharmaceuticals Spolka Akcyjna Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania
RU2535020C1 (ru) 2014-01-23 2014-12-10 Карпов Алексей Николаевич Фармацевтическая композиция седативного и спазмолитического действия
MY177906A (en) * 2014-02-06 2020-09-25 Sequential Medicine Ltd Composition and method for aiding sleep
ES2706302T3 (es) * 2014-05-05 2019-03-28 Sanofi Aventis Deutschland Granulado de disolución rápida
PT2974733T (pt) 2014-07-14 2016-10-24 Dr Willmar Schwabe Gmbh & Co Kg Combinação de extracto de raiz de valeriana e óleo de alfazema para tratamento de distúrbios de sono

Also Published As

Publication number Publication date
RU2018142019A (ru) 2020-06-08
KR20190008265A (ko) 2019-01-23
US10342873B2 (en) 2019-07-09
EP3452020A4 (en) 2020-02-19
US20170319697A1 (en) 2017-11-09
EP3452020A1 (en) 2019-03-13
US20190321475A1 (en) 2019-10-24
JP2019514977A (ja) 2019-06-06
CN109310638A (zh) 2019-02-05
US20210401990A1 (en) 2021-12-30
WO2017192843A1 (en) 2017-11-09
JP7576905B2 (ja) 2024-11-01
RU2018142019A3 (enExample) 2020-09-16
US11141484B2 (en) 2021-10-12
MX2018013569A (es) 2019-03-14
AU2017260019A1 (en) 2018-11-22
US11701425B2 (en) 2023-07-18
CN117482062A (zh) 2024-02-02
JP2022116251A (ja) 2022-08-09
US11141485B2 (en) 2021-10-12
JP7577090B2 (ja) 2024-11-01
US20190328881A1 (en) 2019-10-31
BR112018072795A2 (pt) 2019-04-30
CA3023305A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
US10888522B2 (en) Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
CN1119993C (zh) 醋氨酚、假麻黄碱、扑尔敏和可有可无的美沙芬的旋转制粒及包衣
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
US11701425B2 (en) Valerian composition and related methods
AU2020209940A1 (en) Solid micronized melatonin composition
JP5718937B2 (ja) パーキンソン病を治療するための医薬組成物及びその調製方法
KR20090086128A (ko) 메만틴 약학 조성물
WO2024165966A1 (en) Gastroretentive extended release compositions of riociguat
KR20160105662A (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
TR201721036A2 (tr) Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari
BR122021015452B1 (pt) Uso de valeriana e de um agente acidificante na fabricação de uma composição para tratar dor, insônia, ansiedade, deficiência de melatonina, distúrbio de sono e/ou um distúrbio de ritmo circadiano e método para produção de uma forma de dosagem farmacêutica de valeriana estável em armazenamento
BR112018072795B1 (pt) Comprimido ou cápsula consistindo em valeriana dentro de uma matriz polimérica acidificada
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물
JP2024074793A (ja) 医薬組成物
AU2024312609A1 (en) A gastroretentive composition comprising apixaban
CA2456410A1 (en) Stabilised pharmaceutical composition comprising an extented release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
KR20100102441A (ko) 제어방출형 고혈압 치료제의 조성물 및 그 제조방법
WO2011107922A2 (en) Extended release composition of milnacipran

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240701

Free format text: ST27 STATUS EVENT CODE: A-4-4-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: COVER PAGE PUBLISHED

Effective date: 20240701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W00-W00-W604 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: GRANT DOWNLOADED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-4-4-W00-W00-W604 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: GRANT DOWNLOADED

Effective date: 20240702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401